<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482701</url>
  </required_header>
  <id_info>
    <org_study_id>91038126</org_study_id>
    <nct_id>NCT02482701</nct_id>
  </id_info>
  <brief_title>The Captivator EMR Registry</brief_title>
  <official_title>An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm performance of the Captivator™ EMR device for resection of early neoplasia in
      Barrett's Esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Successful endoscopic resection defined as complete resection of the delineated area, including all delineation markings, in a single procedure.</measure>
    <time_frame>Procedure</time_frame>
    <description>Successful resection is assessed during the EMR procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of resections per procedure</measure>
    <time_frame>Procedure</time_frame>
    <description>The number of resection per procedure is assessed during the EMR Procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>Procedure</time_frame>
    <description>Total procedure time is assessed during the EMR procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seriousness and severity of adverse events related to the Captivator™ EMR device or procedure</measure>
    <time_frame>Procedure through 30 days post EMR procedure</time_frame>
    <description>Study subjects will have follow-up visits after the EMR procedure during which the occurrence of adverse events related to the Captivator EMR procedure or device will be assessed. These visits will occur at the following time points:
Immediately following the EMR procedure (Post procedure evaluation)
48 hour telephone call
30 day telephone call
Unscheduled clinic visits will be performed in-between protocol required follow-up, as necessary.
Once the 30 day phone call is complete, the subject will have completed the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accessory devices used during the procedure for complication management</measure>
    <time_frame>Procedure</time_frame>
    <description>Accessory device use is assessed during the EMR procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to endoscopically manage complications without the need for additional interventions</measure>
    <time_frame>Procedure</time_frame>
    <description>Endoscopic management of complications is assessed during the EMR procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accessory devices used to complete the resection procedure</measure>
    <time_frame>Procedure</time_frame>
    <description>Accessory devices used to complete resection is assessed during the EMR procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathology</measure>
    <time_frame>Post Procedure</time_frame>
    <description>Histopathology of resection specimens is performed per standard of practice at each participating study center. Results are expected within approximately 7 days of the EMR procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Barrett's Esophagus</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Captivator™ EMR</intervention_name>
    <description>The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Barrett's Esophagus patients with early neoplasia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years.

          2. Barrett's esophagus with a visible abnormality confirmed upon prior endoscopy. A
             visible abnormality is described as meeting one or more of the following definitions:

               -  Lesion is detected as visible based on white light imaging with any macroscopic
                  appearance according to the Paris Classification and is also endoscopically
                  resectable.

               -  Lesion is detected by narrow band imaging (NBI), but without any other specific
                  characteristics for a visible lesion.

               -  Lesion is confirmed to contain high grade dysplasia and/or carcinoma upon prior
                  biopsy.

          3. Subject is scheduled for endoscopic resection of present neoplasia

          4. Subject is amenable to EMR with no suspicion of submucosal invasion, based on the
             macroscopic appearance and/or endosonography upon earlier endoscopy.

          5. Subject is taking PPI (Proton Pump Inhibitor) BID (Twice Daily) 40 mg (or equivalent
             dosage).

          6. Subject is willing to participate, fully understands the content of the informed
             consent form, and signs the informed consent form.

        Exclusion Criteria:

          1. Subject has previously undergone endoscopic therapy for esophageal neoplasia,
             including (but not limited to) cryospray therapy, laser treatment, photodynamic
             therapy, endoscopic mucosal resection, radiofrequency ablation, argon plasma
             coagulation or radiotherapy.

          2. Presence of esophageal stenosis preventing passage of a therapeutic gastroscope.

          3. Endoscopically visible scarring by any cause of the intended treatment zone.

          4. Esophageal varices.

          5. Subject has known or suspected esophageal perforation.

          6. Coagulation disorders or anti-coagulant therapy which cannot be discontinued (aspirin
             allowed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Bergman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Burbage</last_name>
    <phone>508-683-4387</phone>
    <email>burbagea@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wallace, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael B. Wallace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Lutzke, CRC, CCRP</last_name>
      <phone>507-255-7495</phone>
      <email>lutzke.lori@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth K. Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Bourke, MD</last_name>
      <email>laurabokody@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Bourke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TBD</last_name>
    </contact>
    <investigator>
      <last_name>Raf Bisschops, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cirocco, RN</last_name>
      <email>ciroccom@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Norman Marcon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Bruder</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Brookman-Amissah</last_name>
      <email>dominic.brookman-amissah@barmherzige-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Pech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EVK Krankenhaus</name>
      <address>
        <city>Dusseldorf</city>
        <zip>D-40217</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TBD</last_name>
    </contact>
    <investigator>
      <last_name>Horst Neuhaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Instituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TBD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>AZ</state>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine Sodermeger</last_name>
      <phone>+31-20-5663531</phone>
      <email>c.m.sodermeger@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Jacques Bergman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>EJ</state>
        <zip>5623</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam van Loon</last_name>
      <email>mirjam.v.loon@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Erik Schoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwgein</city>
        <state>NL</state>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim van der Meulen</last_name>
      <phone>+31-30-6092295</phone>
      <email>k.van.der.meulen@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Bas Weusten, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anniek Gotink, MD</last_name>
      <phone>+31-1-070-330-40</phone>
      <email>a.gotink@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Arjun D. Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Nuckcheddy-Grant</last_name>
      <phone>+44-1223330018</phone>
      <email>tn278@mrc-cu.cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Massimiliano Di Pietro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gideon Lipman</last_name>
      <email>g.lipman@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rehan Haidry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham Digestive Disease Centre, NIHR</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacobo Ortiz, MD</last_name>
      <email>jacobo.Ortizfernndezsordo@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Krish Ragunath, MD FRCP FASGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>June 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EMR</keyword>
  <keyword>EAC</keyword>
  <keyword>Barrett's Neoplasia</keyword>
  <keyword>Multiband Mucosectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
